Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been assigned an average rating of “Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.57.
Several equities research analysts have commented on the stock. Noble Financial restated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research note on Monday, August 12th. JPMorgan Chase & Co. decreased their price objective on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 11th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Saturday, August 10th. Jefferies Financial Group decreased their price objective on shares of TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, July 15th. Finally, Oppenheimer set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 22nd.
Shares of NASDAQ:TXMD opened at $2.64 on Friday. The firm’s 50 day moving average is $2.50 and its two-hundred day moving average is $3.76. TherapeuticsMD has a 52 week low of $1.82 and a 52 week high of $6.94. The firm has a market capitalization of $658.54 million, a P/E ratio of -4.47 and a beta of 1.90. The company has a current ratio of 5.17, a quick ratio of 4.99 and a debt-to-equity ratio of 24.29.
In other TherapeuticsMD news, insider John C.K. Iv Milligan bought 15,000 shares of TherapeuticsMD stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $47,400.00. Following the completion of the acquisition, the insider now owns 1,472,419 shares of the company’s stock, valued at approximately $4,652,844.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Angus C. Russell bought 35,000 shares of TherapeuticsMD stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average price of $2.83 per share, with a total value of $99,050.00. Following the completion of the acquisition, the director now directly owns 73,500 shares of the company’s stock, valued at approximately $208,005. The disclosure for this purchase can be found here. Insiders bought 170,549 shares of company stock valued at $493,167 over the last quarter. Insiders own 18.91% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. boosted its holdings in TherapeuticsMD by 45.5% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 24,973 shares of the company’s stock worth $65,000 after buying an additional 7,810 shares in the last quarter. Bamco Inc. NY boosted its holdings in TherapeuticsMD by 41.8% during the second quarter. Bamco Inc. NY now owns 3,331,500 shares of the company’s stock worth $8,662,000 after buying an additional 981,500 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in TherapeuticsMD during the second quarter worth approximately $2,218,000. UBS Asset Management Americas Inc. boosted its holdings in TherapeuticsMD by 19.6% during the second quarter. UBS Asset Management Americas Inc. now owns 143,932 shares of the company’s stock worth $374,000 after buying an additional 23,539 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in TherapeuticsMD by 100.0% during the second quarter. Jane Street Group LLC now owns 120,607 shares of the company’s stock worth $314,000 after buying an additional 60,296 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Recommended Story: Different Types of Derivatives
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.